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Am J Med Genet Part A 9999A:1–7.De novo mutations (DNM) in SYNGAP1, encoding Ras/Rap
GTPase-activating protein SynGAP, have been reported in indi-
viduals with nonsyndromic intellectual disability (ID). We iden-
tified10previously unreported individualswithSYNGAP1DNM;
seven via the Deciphering Developmental Disorders (DDD)
Study, one through clinical analysis for copy number variation
and the remaining two (monozygotic twins) via a researchmulti-
genepanel analysis. Sevenof thenineheterozygousmutations are
likely to result in loss-of-function (3 nonsense; 3 frameshift; 1
whole genedeletion). The remaining twomutations, oneofwhich
affected the monozygotic twins, were missense variants. Each
individual carrying a DNM in SYNGAP1 hadmoderate-to-severe
ID and 7/10 had epilepsy; typically myoclonic seizures, absences
or drop attacks. 8/10 had hypotonia, 5/10 had significant consti-
pation, 7/10 had wide-based/unsteady gait, 3/10 had strabismus,
and 2/10 had significant hip dysplasia. A proportion of the
affected individuals had a similar, myopathic facial appearance,
with broad nasal bridge, relatively long nose and full lower lip
vermilion. A distinctive behavioral phenotype was also observed
with aggressive/challenging behavior and significant sleep prob-
lems being common. 7/10 individuals had MR imaging of the
brain each of which was reported as normal. The clinical features
of the individuals reported here show significant overlap with
those associated with 6p21.3 microdeletions, confirming that
haploinsufficiency for SYNGAP1 is responsible for both disor-
ders. 2015 Wiley Periodicals, Inc.15 Wiley Periodicals, Inc. 1
2 AMERICAN JOURNAL OF MEDICAL GENETICS PART AKey words: SYNGAP1; 6p21.3 microdeletion; intellectual
disability; epilepsy; syndrome; hypertrichosis; strabismus; hip
dysplasia; DDD study; behavioral phenotype
INTRODUCTION
De novo mutations are an important cause of moderate and
severe intellectual disability (ID). Heterozygous, de novo loss-
of-function mutations in SYNGAP1 have been described in 26
individuals to date [Hamdan et al., 2009, 2011a, b; Krepischi
et al., 2010; Pinto et al., 2010; Vissers et al., 2010; Zollino et al.,
2011; de Ligt et al., 2012; Rauch et al., 2012; Berryer et al., 2013;
Carvill et al., 2013; Writzl and Knegt, 2013; Redin et al.,
2014]. SYNGAP1 encodes Ras/Rap GTPase-activating protein
SynGAP, which is a major component of the post-synaptic
density that regulates synaptic plasticity and ERK/MAPK signal-
ing probably via N-methyl-d-aspartate (NMDA) receptor acti-
vation [Komiyama et al., 2002; Muhia et al., 2010]. SYNGAP1
[603384] has been coded in Online Mendelian Inheritance
in Man (OMIM
1
) as causing mental retardation, autosomal
dominant 5 [612621].
In 2009, Hamdan et al. first reported the sequencing of SYN-
GAP1 in 94 apparently nonsyndromic individuals with intellectual
disability; they found de novo mutations in three, thus first-
describing this gene as a cause of nonsyndromic intellectual
disability (ID) in humans [Hamdan et al., 2009]. This group
subsequently published eight further affected individuals through
re-sequencing predominantly ID cohorts enriched for epilepsy
[Hamdan et al., 2011a, b; Berryer et al., 2013]. Carvill et al.
performed massively parallel sequencing in 500 individuals with
epileptic encephalopathy and identified four patients with de novo
SYNGAP1 mutations [Carvill et al., 2013]. Further patients have
been described as part of large next generation sequencing studies
of individuals with ID [Vissers et al., 2010; de Ligt et al., 2012;
Rauch et al., 2012; Redin et al., 2014].
In addition, there have been four individuals with genomic
deletions of 6p23.1 involving SYNGAP1, and one with a de novo
apparently balanced reciprocal translocation in which one of
the breakpoints disrupts SYNGAP1 [Krepischi et al., 2010;
Pinto et al., 2010; Klitten et al., 2011; Zollino et al., 2011;
Writzl and Knegt, 2013]. Thus the 26 individuals reported to
date consist of 21 intragenic mutations, four whole gene
deletions, and one translocation. To date, facial images have
only been published in six individuals: three in the seminal
Hamdan et al. paper, plus three single patients in subsequent
papers [Hamdan et al., 2009; Zollino et al., 2011; Rauch et al.,
2012; Writzl and Knegt, 2013].
Here, we present molecular and clinical information on 10
previously unreported individuals with de novo mutations in
SYNGAP1, most of whom were diagnosed using trio exome
sequencing of individuals with undiagnosed developmental dis-
orders. The relatively consistent pattern of clinical features and
behavioral anomalies observed in these individuals and in previ-
ously reported individuals suggests that there is an emerging
SYNGAP1-associated syndrome.METHODS
Patient Ascertainment
Seven of the 10 affected individuals were recruited via UK NHS
Regional Genetics Services to the Deciphering Developmental
Disorders (DDD) study (www.ddduk.org). The eighth individual
(7; Table I) was identified as part of routine investigation of ID
via a UK NHS paediatric genetics clinic. These eight individuals
were seen by the same Paediatric Geneticist (MJP) in addition to
the referring Clinical Geneticists. The ninth and tenth individuals
are monozygotic twins who were referred for genetic evaluation
to the local multi-disciplinary clinic for children with intellectual
disability. See Table I for a summary of the clinical and molecular
findings. The Supporting Information online provides additional
clinical details.Mutation Analysis
For the seven individuals identified via the DDD study,
trio-based exome sequencing was performed on the affected
individual and their parents, as previously described [Wright
et al., 2014]. Each affected individual has also had a high-
resolution analysis for copy number abnormalities using array-
based comparative genomic hybridization (aCGH). Putative de
novo mutations were identified from exome data using
DeNovoGear software [Ramu et al., 2013] and were validated
using targeted Sanger sequencing.
The eighth individual (7; Table I) was identified as having a
0.39Mb deletion of 6p21.32p21.31, via a service ISCA 8 60K
BlueGnome Array. The ninth and tenth individuals are mono-
zygous twins from Belgium, who were identified through a local
multi-gene panel and were validated using targeted Sanger
sequencing.RESULTS
SYNGAP1 Mutations
The validated de novo mutations are detailed in Table I. There
were 10 individuals, but two are monozygotic twins, so we
describe eight mutations and one deletion. Three individuals
had nonsense mutations; three had frameshift mutations
resulting in early stop codons. One individual (2; Table I)
had a missense mutation c.509G>A (ENST00000418600);
p.Arg170Gln (ENSP00000403636.2). On SIFT analysis; this
was labeled “Deleterious” with a score of 0.01 and on PolyPhen
analysis “Possibly damaging” with a score of 0.529. This mutated
residue lies within the PH domain (Prosite PS50003) of SynGAP.
The monozygotic twins (9 and 10; Table I) had a missense
mutation c.1081T>C (ENST00000418600); p.Leu327Pro
(ENSP00000403636). The SIFT score is 0, “Deleterious”, and
the PolyPhen is 0.983, “Probably Damaging”. This mutation lies
within the C2 domain, which is required for RapGAP activity.
One individual (7; Table I) had a 0.39Mb genomic deletion,
which encompassed the entire SYNGAP1 gene and 18 other
genes.
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Birth weight was normal (z score between 2 and 2) for all of the
affected individuals. Postnatal growth was normal in five
individuals (1, 2, 5, 8 and 9; Table I). Three of 10 had mild
microcephaly (z score between 2.5 and 3), with one of these
also having weight on a similar centile (4; Table I). Two indi-
viduals had significant short stature (Patients 6 and 10; Table I),
one of whom was also significantly underweight (Patient 10;
Table I).Development
Global delay in developmental milestones was present in all
patients with an unusual temporal sequence seen in some patients.
For example, Patient 5 (Table I) did not sit unaided until
15 months, but walked unaided at 17 months. Typically indepen-
dent walking was achieved in the third year of life with the
subsequent gait being wide-based and unsteady. Language acqui-
sition was highly variable within this group. Expressive language
was delayed withmost children using a limited vocabulary of single
words. None of the affected individuals were toilet-trained at the
time of assessment.FIG. 1. Faces of individuals with SYNGAP1 haploinsufficiency. Facial phot
2 months (b); Patient 3 at 7 years, 9 months (c); Patient 4 at 3 years,
12 years, 10 months (f); Patient 7 at 5 years, 7 months (g); Patient 8 a
(i and j). The most common shared facial characteristics are almond-sha
exception of Patient 5 (e), the others have a mildly myopathic appearan
(c), 4 (d), 6 (f), 7 (g) and 9 (i) and 10 (j) have relatively long noses; P
ears with protuberant lobes. Patients 1 (a), 6 (f) and 9 (i) and 10 (j) w
degree of ptosis. Patient 6 (f) has a missing central incisor due to traum
this series, differs significantly in appearance from the others.Behavior
Seven of the ten individuals showed general hyperexcitability and
aggressive behavior, often directed towards others. A disturbed
sleep pattern was reported in all patients, with almost all being
treated with, or having had a therapeutic trial of, Melatonin.
Anecdotally, families reported a high pain threshold and hyper-
acusis in some affected individuals.Neurology
Seven of the 10 individuals had seizures, most commonly complex
and generalized, including myoclonic, drop attacks, and absences.
Congenital central hypotonia was common. Most of the affected
individuals required ankle splints and/or Piedro boots to aid with
walking. Seven individuals have had MR imaging of their brains
and in each patient this was reported as normal.Facial Features
The facial appearance of the ten affected individuals is shown in
Figure 1. The most common shared facial characteristics are
almond-shaped palpebral fissures, which slant downwards slightly.ographs of Patient 1 at 7 years, 3 months (a); Patient 2 at 8 years,
2 months (d); Patient 5 at 8 years, 4 months (e); Patient 6 at
t 8 years, 7 months (h); and Patients 9 and 10 at 8 years, 3 months
ped palpebral fissures, which slant downwards slightly. With the
ce, with an open mouth and relatively full lower lip. Patients 1 (a), 3
atients 2 (b), 4 (d), 5 (e), 6 (f), 7 (g) and 8 (h) have relatively long
ere thought to have relatively deep-set eyes and Patient 8 (h) has a
a. We do not believe that Patient 7 (g), the only deletion patient in
PARKER ET AL. 5All but one had amildlymyopathic appearance. An open-mouthed
appearance, with a relatively full lower lip vermilion was common,
as was a low-hanging columella. 7/10 had relatively long noses
(sometimes with under-development of the ala nasi); 6/10 had
relatively long ears with protuberant lobes; 4/10 had relatively
deep-set eyes; and one had a degree of ptosis. There was no obvious
difference in facial appearance between the deletion and intragenic
mutation patients.Other Features
Five of the individuals had constipation, requiring medical thera-
pies; three individuals had fine hirsutism, especially noticeable over
limbs and spine; two had significant hip dysplasia, requiring
surgical management; three had a kyphosis or kyphoscoliosis;
and one had a pectus excavatum (Table I).DISCUSSION
SYNGAP1 was originally reported as causing non-syndromal
intellectual disability [Hamdan et al., 2009]. Supplementary
Table I summarizes the available clinical data on the 26 individuals
who have been reported to date with presumed causative
mutations in SYNGAP1 or deletions or translocations involving
this gene [Hamdan et al., 2009, 2011a, b; Krepischi et al., 2010;
Pinto et al., 2010; Vissers et al., 2010; Cook, 2011; Klitten et al.,
2011; Zollino et al., 2011; Clement et al., 2012; de Ligt et al., 2012;
Rauch et al., 2012; Berryer et al., 2013; Carvill et al., 2013; Writzl
and Knegt, 2013; Dyment et al., 2014; O’Roak et al., 2014;
Redin et al., 2014]. De novomutations in this gene are undoubtedly
a significant cause of intellectual disability, accounting for 0.62%of
all the patients in the DDD Study [Wright et al., 2014] and major
contributors to other cohorts that have been studied (Supplemen-
tary Table II).
The original designation of the phenotype associated with
SYNGAP1 haploinsufficiency as non-syndromal is understandable
given the generally normal antenatal growth parameters and the
relative normality of post-natal growth. In addition, all patients
have amoderate-to-severe intellectual disability with few structural
anomalies reported on brain imaging. The genomic pathology is
also remarkably consistent with almost all patients having hetero-
zygous, de novo, loss of functionmutations. The associated genetic
mechanism is very likely to be haploinsufficiency given the simi-
larity of the intragenic mutations with the whole gene deletions.
Although there is wide variability in the type and severity of the
clinical features associated with SYNGAP1 haploinsufficiency,
some aspects of the phenotype show a level of consistency that
suggests SYNGAP1 haploinsufficiency may be associated with a
clinically recognizable syndrome. The seizure type and the behav-
ioral phenotype were relatively consistent in our cohort. Myoclon-
ic, absence and drop attack seizures are typical, both in the reported
individuals and those presented in this paper. General hyperexcit-
ability, sleep disturbance and aggressive behavior, often directed
towards others, are common features in our cohort and are
mentioned in some of the previously reported patients. Clearly
these distressing behavioral components of the phenotype require
further investigation. Facial photographs were not available inmost of the previous reports, but in the cohort presented here a
subtle but consistent facial appearance is suggested, although
further observations will be required to determine if this is in
any way discriminative. The pattern of growth may also be helpful
in making a clinical diagnosis. Six of 18 reported patients with
postnatal head circumferences recorded, and 3/10 of the patients
reported here, had measurements of two standard deviations
below the mean for their age. A mild postnatal microcephaly is
clearly over-represented in this group.
In our cohort, 8/10 patients had previously been investigated for
Angelman syndrome. There are some similarities with this
condition, although we believe that they are clinically distinguish-
able. Nevertheless, we believe that SYNGAP1 should also be added
to the expanding list of differential diagnoses for Angelman
syndrome or patients presenting with Angelman-like features.CONCLUSION
SYNGAP1 has previously been described as presenting in a non-
syndromal manner. Mutations in this gene have been found to be a
relatively-common cause of intellectual disability in large-scale
massively parallel sequencing studies, where subjects are usually
recruited because a clinical syndromal diagnosis has not previously
been made. It is arguable whether the term non-specific may be
more appropriate tomany subjects recruited into such studies, who
most likely represent a heterogeneous mix of those genuinely non-
syndromal, but also of some syndromes more subtle in their
associations and/or dysmorphology. For SYNGAP1 we consider
discriminative features in individuals with moderate-to-severe ID
to be the characteristic facial features, seizure type and behavioral
phenotype (generalized hyper-excitability, sleep disturbance and a
propensity to aggression). It is not yet clear if hypotonia, hip
dysplasia, strabismus, wide-based/unsteady gait, fine hirsutism
(limbs and spine), and significant constipation are helpful dis-
criminators. Some patients have microcephaly, but growth param-
eters are generally within the normal range.ACKNOWLEDGMENTS
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